Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis

Clinical Drug Investigation

Volumn 33, Issue 4, 2013, Pages 233-241

  Birmingham, Bruce K ^a   Swan, Suzanne K ^b   Puchalski, Tom ^a   Mitchell, Pat ^a   Azumaya, Connie ^a   Zalikowski, Julie ^a   Wang, Yi ^a,c  

^a ASTRAZENECA   (United Kingdom)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PYRIMIDINES; RENAL DIALYSIS; SULFONAMIDES;

EID: 84877012571     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0071-3     Document Type: Article

References (41)

1. US Renal Data System, USRDS 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112-9.
3. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297-304.
4. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in haemodialysis patients. Am J Kidney Dis. 2005;45(1):119-26.
5. Wanner C, Krane V, März W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48.
6. Fellström BC, Jardine AG, Schmieder RE, et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407.
7. Baigent C, Landray MJ, Reith C, et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
8. Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335-41.
9. März W, Genser B, Drechsler C, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin and low density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6(6):1316-25.
10. Fellström BC, Holdaas H, Jardine AG, et al. Normalisation of CRP and LDL-C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment - a post hoc analysis of the AURORA trial [abstract no. TH-PO473]. J Am Soc Nephrol. 2010;21:218A.
11. Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69-76.
12. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152-60.
13. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25(11):2822-35.
14. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553-63.
15. Tzeng TB, Schneck DW, Birmingham BK, et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008;24(9):2575-85.
16. ® Summary of Product Characteristics. http://www.medicines.org.uk/emc/document.aspx?documentid=11976. Accessed March 2012.
17. ® (rosuvastatin calcium) Full Prescribing Information. AstraZeneca, Wilmington, Delaware 19850, USA. http://www1. astrazeneca-us.com/pi/crestor.pdf. Accessed March 2012.
18. Bologa R, Levine D, Parker T, et al. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. Clin Nephrol. 2009;72(6):437-41.
19. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54(5):472-7.
20. Martin PD, Warwick MJ, Dane AL, et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25(8):2215-24.
21. Warwick MJ, Dane AL, Raza A, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract MoP19:W6]. Atherosclerosis. 2000;151(1):39.
22. Data on file:Domenic Sica MD (Principal Investigator). The pharmacokinetics and pharmacodynamics of ZD4522 (20 mg) in subjects with normal and impaired renal function. AstraZeneca Study 4522IL/0017, AstraZeneca, Wilmington, DE, USA; 2001.
23. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009;86(5):553-6.
24. Leblond FA, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28(11):1317-20.
25. Leblond F, Guévin C, Demers C, et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12(2):326-32.
26. Nolin TD, Frye RF, Sadr H, et al. The pharmacokinetics of fexofenadine but not midazolam are altered in end-stage renal disease. Clin Pharmacol Ther. 2008;83(Suppl. 1):S58.
27. Anzai N, Endou H. Renal drug transporters and nephrotoxicity. In: Proceedings of the 6th world congress on alternatives and animal use in the life sciences, August 21-25, 2007, Tokyo, Japan. AATEX 2007; 14 Suppl.: 447-52.
28. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065-74.
29. Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol. 2007;64(2):165-73.
30. Vanholder R, Glorieux G, de Smet R, et al. New insights in uremic toxins. Kidney Int. 2003;63(Suppl. 84):S6-10.
31. Fuh MM, Lee CM, Jeng CY, et al. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int. 1990;37(5):1295-300.
32. Alabakovska SB, Todorova BB, Labudovic DD, et al. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002;35(3):211-6.
33. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293-301.
34. Janicki K, Solski J, Janicka L, et al. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients. Ann Univ Mariae Curie Sklodowska Med. 2004;59(1):459-66.
35. Jamoussi K, Ayedi F, Abida N, et al. Lipid profile in maintenance haemodialysis [in French]. Pathol Biol (Paris). 2005;53(4):217-20.
36. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388-99.
37. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.
38. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(Suppl. 3):S1-92.
39. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-32.
40. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
41. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266-73.